These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 28636828

  • 21. Directly Observable Behavioral Effects of Lorcaserin in Rats.
    Serafine KM, Rice KC, France CP.
    J Pharmacol Exp Ther; 2015 Dec; 355(3):381-5. PubMed ID: 26384326
    [Abstract] [Full Text] [Related]

  • 22. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Bohula EA, Scirica BM, Fanola C, Inzucchi SE, Keech A, McGuire DK, Smith SR, Abrahamsen T, Francis BH, Miao W, Perdomo CA, Satlin A, Wiviott SD, Sabatine MS.
    Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
    [Abstract] [Full Text] [Related]

  • 23. Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release.
    Hurt RT, Mundi MS, Ebbert JO.
    Diabetes Metab Syndr Obes; 2018 Aug; 11():469-478. PubMed ID: 30233224
    [Abstract] [Full Text] [Related]

  • 24. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison.
    Chilton M, Dunkley A, Carter P, Davies MJ, Khunti K, Gray LJ.
    Diabetes Obes Metab; 2014 Mar; 16(3):237-47. PubMed ID: 23964810
    [Abstract] [Full Text] [Related]

  • 25. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.
    Halpern B, Halpern A.
    Expert Opin Drug Saf; 2015 Feb; 14(2):305-15. PubMed ID: 25563411
    [Abstract] [Full Text] [Related]

  • 26. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D, Behan D.
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [Abstract] [Full Text] [Related]

  • 27. Tolerability and safety of the new anti-obesity medications.
    Hainer V, Aldhoon-Hainerová I.
    Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
    [Abstract] [Full Text] [Related]

  • 28. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?
    Kolotkin RL, Crosby RD, Wang Z.
    Clin Obes; 2017 Dec; 7(6):347-353. PubMed ID: 28815987
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
    Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, APD356-004 Study Group.
    Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists.
    Higgins GA, Zeeb FD, Fletcher PJ.
    J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522
    [Abstract] [Full Text] [Related]

  • 35. Novel oral anti-obesity agents: new perspectives with lorcaserin?
    Gallwitz B.
    Drugs; 2013 Apr; 73(5):393-5. PubMed ID: 23532530
    [No Abstract] [Full Text] [Related]

  • 36. Past and present of antiobesity agents: focus on monoamine modulators.
    Khorassani FE, Misher A, Garris S.
    Am J Health Syst Pharm; 2015 May 01; 72(9):697-706. PubMed ID: 25873617
    [Abstract] [Full Text] [Related]

  • 37. Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.
    Anastasio NC, Sholler DJ, Fox RG, Stutz SJ, Merritt CR, Bjork JM, Moeller FG, Cunningham KA.
    Neuropharmacology; 2020 May 15; 168():108009. PubMed ID: 32145488
    [Abstract] [Full Text] [Related]

  • 38. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL, Bello NT.
    Expert Opin Drug Saf; 2014 Jun 15; 13(6):831-41. PubMed ID: 24766397
    [Abstract] [Full Text] [Related]

  • 39. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
    Bays HE.
    Expert Rev Cardiovasc Ther; 2011 Mar 15; 9(3):265-77. PubMed ID: 21438803
    [Abstract] [Full Text] [Related]

  • 40. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
    Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Dosa PI, Covel JA, Ren A, Webb RR, Beeley NR, Martin M, Morgan M, Espitia S, Saldana HR, Bjenning C, Whelan KT, Grottick AJ, Menzaghi F, Thomsen WJ.
    J Med Chem; 2008 Jan 24; 51(2):305-13. PubMed ID: 18095642
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.